LifeTech Scientific Corporation (HK:1302) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LifeTech Scientific Corporation has announced the successful completion of a one-year follow-up study for its IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System, showcasing impressive safety and effectiveness results. With a target lesion failure rate of 2.9% and zero cardiac deaths reported, the innovative scaffold is poised for CE registration approval in the European Union. This development promises significant advancements for patients with coronary heart disease worldwide.
For further insights into HK:1302 stock, check out TipRanks’ Stock Analysis page.